<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108703</url>
  </required_header>
  <id_info>
    <org_study_id>052-2015</org_study_id>
    <nct_id>NCT03108703</nct_id>
  </id_info>
  <brief_title>Assessment of QoL and Outcomes With SBRT for RCC</brief_title>
  <acronym>AQuOS-RCC</acronym>
  <official_title>Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juravinski Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic body radiotherapy (SBRT) is an emerging radiotherapy technique that precisely&#xD;
      delivers high doses of radiation to tumours. It has been investigated as definitive treatment&#xD;
      for an increasing variety of primary tumours including lung, liver, prostate, and now renal&#xD;
      cell carcinoma (RCC). The principal aims of this study are to prospectively assess quality of&#xD;
      life (QoL) and oncologic outcomes in non-surgical patients who receive SBRT for the treatment&#xD;
      of RCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an evolving body of literature that shows high rates of tumour control and minimal&#xD;
      associated toxicities with SBRT to treat RCC. However, the majority of published evidence is&#xD;
      retrospective in nature, and there is a scarcity of data on the impact on quality of life and&#xD;
      cost-effectiveness of kidney SBRT.&#xD;
&#xD;
      The principal aims of this multicentre study are to prospectively assess QoL and oncologic&#xD;
      outcomes in non-surgical patients who receive SBRT for the treatment of primary renal cell&#xD;
      carcinoma.&#xD;
&#xD;
      The study population will include 30 consecutive patients treated with kidney SBRT on a&#xD;
      conventional linear accelerator (35-40 Gy in 5 fractions) at the Odette Cancer Centre,&#xD;
      Sunnybrook Health Sciences Centre, University of Toronto (OCC) and the Juravinski Cancer&#xD;
      Center, Hamilton Health Sciences Centre, McMaster University (JCC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient Quality of Life</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>To evaluate quality of life scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To assess health utility scores and correlate with QoL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate local control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologic Outcomes</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To evaluate overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-Related Toxicity</measure>
    <time_frame>Up to 5 years after completion of treatment</time_frame>
    <description>To report number of participants with treatment-related toxicities as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RCC patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT</intervention_name>
    <description>35-40 Gy delivered in 5 fractions</description>
    <arm_group_label>SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥18 years old&#xD;
&#xD;
          -  Medically inoperable or patient who refuses surgery&#xD;
&#xD;
          -  Histologic diagnosis of RCC where possible, or radiologic evidence of growth on&#xD;
             surveillance&#xD;
&#xD;
          -  Lesion ≥2.5cm or recurrent lesion following local ablative therapy&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Participants must be able to understand the English-language or with the aid of a&#xD;
             translator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ECOG ≥3&#xD;
&#xD;
          -  Prior abdominal radiation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odette Cancer Centre, Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. William Chu</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>RCC</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Ablative Radiotherapy</keyword>
  <keyword>SABR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

